Semaglutide
GLP-1 Receptor Agonist for Type 2 Diabetes and Weight Management
📊 Quick Facts About Semaglutide
Key Takeaways About Semaglutide
- Dual indication: Semaglutide is approved for both type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy) in adults
- Cardiovascular benefits: Clinical trials have demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes
- Oral or injectable: Available as the first oral GLP-1 receptor agonist (Rybelsus) and as a once-weekly subcutaneous injection (Ozempic, Wegovy)
- Gastrointestinal side effects are most common: Nausea, diarrhea, and vomiting are the most frequently reported side effects but typically improve over time
- Special dosing instructions for oral form: Oral semaglutide must be taken on an empty stomach with a small amount of water, followed by a 30-minute fasting period
What Is Semaglutide and What Is It Used For?
Semaglutide is a GLP-1 receptor agonist medication used to lower blood sugar levels in adults with type 2 diabetes and for chronic weight management in adults with obesity or overweight. It works by mimicking the natural hormone GLP-1, which stimulates insulin release, reduces glucagon secretion, slows stomach emptying, and decreases appetite.
Semaglutide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs work by activating the same receptors as the naturally occurring incretin hormone GLP-1, which plays a key role in blood sugar regulation and appetite control. Semaglutide has a 94% amino acid sequence similarity to human GLP-1 and has been structurally modified to resist breakdown by the enzyme DPP-4, giving it a much longer half-life of approximately one week.
For type 2 diabetes, semaglutide is used when diet and exercise alone are not sufficient to achieve adequate blood sugar control. It can be prescribed as a sole treatment (monotherapy) when metformin is not suitable, or in combination with other diabetes medications, including metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, or insulin. The injectable form (Ozempic) is administered once weekly, while the oral tablet (Rybelsus) is taken daily.
For chronic weight management, semaglutide (marketed as Wegovy) is approved for adults with a body mass index (BMI) of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. It is used as an adjunct to a reduced-calorie diet and increased physical activity.
Understanding Type 2 Diabetes
Type 2 diabetes is a chronic metabolic condition in which the body does not produce enough insulin or does not respond effectively to the insulin it produces (insulin resistance). This leads to elevated blood sugar levels, which over time can cause serious complications including heart disease, kidney disease, eye disease (retinopathy), and nerve damage (neuropathy). According to the World Health Organization (WHO), approximately 422 million people worldwide have diabetes, with type 2 diabetes accounting for around 90% of all cases.
How Semaglutide Works
Semaglutide exerts its effects through multiple mechanisms. It stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it only enhances insulin release when blood sugar levels are elevated. This glucose-dependent mechanism significantly reduces the risk of hypoglycemia compared to some other diabetes medications. Semaglutide also suppresses the release of glucagon, a hormone that raises blood sugar levels, and slows gastric emptying, which reduces the rate at which glucose enters the bloodstream after meals.
In addition to its glucose-lowering effects, semaglutide acts on appetite-regulating centers in the brain, particularly the hypothalamus, to reduce hunger and food cravings. This central effect, combined with delayed gastric emptying, contributes to the significant weight loss observed in clinical trials. The SUSTAIN and STEP trial programs demonstrated that semaglutide can reduce HbA1c by 1.5–1.8% and body weight by 10–17% depending on the dose and formulation.
Semaglutide is not a form of insulin and should not be used in type 1 diabetes or diabetic ketoacidosis. It is designed specifically for type 2 diabetes and weight management. Always continue following the diet and exercise recommendations agreed upon with your healthcare provider.
What Should You Know Before Taking Semaglutide?
Before taking semaglutide, inform your doctor if you have a history of pancreatitis, thyroid tumors (especially medullary thyroid carcinoma), diabetic retinopathy, kidney problems, or gastroparesis. Semaglutide should not be used during pregnancy or breastfeeding. Tell your doctor about all medications you are taking, as interactions may occur with insulin, sulfonylureas, levothyroxine, and warfarin.
Contraindications
Do not use semaglutide if you are allergic (hypersensitive) to semaglutide or any of the other ingredients in the formulation. Semaglutide is contraindicated in the following situations:
- Type 1 diabetes: Semaglutide is not insulin and should not be used in patients whose bodies do not produce insulin
- Diabetic ketoacidosis: A serious complication of diabetes characterized by high blood sugar, difficulty breathing, confusion, excessive thirst, and a sweet or metallic taste in the mouth
- Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 receptor agonists have caused thyroid C-cell tumors in rodent studies
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Patients with this genetic condition have an increased risk of medullary thyroid cancer
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking semaglutide if you have any of the following conditions or concerns:
Pancreatitis: Semaglutide has been associated with acute pancreatitis. If you experience severe and persistent abdominal pain that may radiate to the back, with or without vomiting, seek medical attention immediately, as this could be a sign of acute pancreatitis. If pancreatitis is confirmed, semaglutide should be permanently discontinued. Patients with a history of pancreatitis should be monitored closely.
Gastrointestinal effects and dehydration: Treatment with semaglutide may cause nausea, vomiting, or diarrhea. These side effects can lead to dehydration (fluid loss), which is particularly dangerous for patients with kidney problems. It is important to drink adequate fluids to prevent dehydration. In rare cases, dehydration has led to worsening of kidney function, including acute kidney injury requiring dialysis.
Diabetic retinopathy: Rapid improvement in blood sugar control has been associated with temporary worsening of diabetic eye disease (retinopathy). If you have diabetic retinopathy, tell your doctor, who may recommend more frequent eye examinations. If you notice changes in your vision while taking semaglutide, contact your doctor promptly.
Hypoglycemia (low blood sugar): When semaglutide is used in combination with a sulfonylurea or insulin, the risk of low blood sugar (hypoglycemia) increases. Your doctor may need to reduce the dose of your sulfonylurea or insulin when starting semaglutide. Warning signs of low blood sugar include cold sweats, pale skin, headache, rapid heartbeat, nausea, excessive hunger, visual changes, drowsiness, weakness, anxiety, confusion, and trembling.
Sudden vision changes: If you experience sudden vision loss or rapid deterioration of vision while taking semaglutide, contact your doctor immediately. This may be due to a very rare side effect called non-arteritic anterior ischemic optic neuropathy (NAION), sometimes referred to as a "stroke of the eye." Your doctor may refer you to an eye specialist for examination.
Gastroparesis (delayed gastric emptying): If you have slow or delayed gastric emptying (gastroparesis), use of semaglutide may lead to serious or severe gastrointestinal side effects. Discuss this with your doctor before starting treatment.
In animal studies, GLP-1 receptor agonists including semaglutide caused thyroid C-cell tumors (including medullary thyroid carcinoma). It is not known whether semaglutide causes thyroid C-cell tumors in humans. Do not use semaglutide if you or a family member have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Surgery
If you are scheduled for surgery under general anesthesia (being put to sleep), inform your doctor and anesthesiologist that you are taking semaglutide. Because semaglutide delays gastric emptying, there is a risk of aspiration during anesthesia. Some guidelines recommend stopping semaglutide before elective surgery; discuss the appropriate timing with your healthcare team.
Pregnancy and Breastfeeding
Semaglutide should not be used during pregnancy, as its effects on the unborn baby are not known. You must use effective contraception while taking semaglutide. If you are planning to become pregnant, discuss with your doctor how to change your treatment, as semaglutide should be discontinued at least 2 months before attempting to conceive. If you become pregnant while using semaglutide, contact your doctor immediately, as your treatment will need to be changed.
Do not use semaglutide while breastfeeding. The medication passes into breast milk, and its effects on the nursing infant are not known. Discuss alternative treatment options with your healthcare provider if you need to breastfeed.
Children and Adolescents
Semaglutide is not recommended for children and adolescents under 18 years of age, as its safety and efficacy have not been established in this age group. Clinical trials in pediatric populations for obesity management are ongoing, but the medication is currently approved only for adult use.
Driving and Operating Machinery
Semaglutide is unlikely to affect your ability to drive or use machines. However, some patients may experience dizziness while taking semaglutide. If you feel dizzy, use extra caution when driving or operating machinery. If you are taking semaglutide in combination with a sulfonylurea or insulin, low blood sugar (hypoglycemia) may impair your concentration. Do not drive or use machines if you experience signs of low blood sugar.
Rybelsus 1.5 mg, 4 mg, and 9 mg tablets contain less than 1 mmol sodium (23 mg) per tablet, meaning they are essentially sodium-free. Rybelsus 25 mg and 50 mg tablets contain 23 mg sodium per tablet, equivalent to approximately 1% of the recommended maximum daily sodium intake for adults.
How Does Semaglutide Interact with Other Drugs?
Semaglutide can interact with levothyroxine (thyroid medication), warfarin (blood thinner), insulin, and sulfonylureas. Because semaglutide delays gastric emptying, it may affect the absorption of other oral medications. Always inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.
Semaglutide can interact with several types of medication. Because it delays gastric emptying, it has the potential to affect the absorption and bioavailability of other oral medications taken at the same time. However, clinical pharmacology studies have shown that these interactions are generally modest for most drugs. Below are the most clinically significant drug interactions to be aware of.
| Drug | Interaction Type | Clinical Significance | Action Required |
|---|---|---|---|
| Insulin | Increased hypoglycemia risk | Major | Reduce insulin dose when starting semaglutide; monitor blood glucose frequently |
| Sulfonylureas (e.g., glimepiride, glipizide) | Increased hypoglycemia risk | Major | Consider reducing sulfonylurea dose; monitor blood glucose |
| Levothyroxine | Altered absorption due to delayed gastric emptying | Moderate | Monitor thyroid function tests when starting or adjusting semaglutide |
| Warfarin (and other oral anticoagulants) | Altered absorption; potential changes in INR | Moderate | Monitor INR more frequently when starting or adjusting semaglutide |
| Oral contraceptives | Delayed gastric emptying may affect absorption | Minor | Clinical studies show no clinically significant effect; no dose adjustment needed |
| Other oral medications | Potential delayed absorption due to gastric emptying | Minor | Take time-sensitive medications at least 30 minutes before or after semaglutide |
Major Interactions
The most clinically significant drug interactions with semaglutide involve medications that also lower blood sugar. When semaglutide is combined with insulin or sulfonylureas, the additive glucose-lowering effect substantially increases the risk of hypoglycemia. Your doctor will likely need to reduce the dose of insulin or sulfonylurea when initiating semaglutide therapy, and may recommend more frequent blood glucose monitoring, particularly during the dose-escalation phase.
Patients taking both semaglutide and insulin should be particularly vigilant about recognizing the signs and symptoms of hypoglycemia and should always carry a source of fast-acting glucose (such as glucose tablets or juice) in case of a hypoglycemic episode.
Moderate Interactions
Levothyroxine, used to treat hypothyroidism (underactive thyroid), may have altered absorption when taken with semaglutide due to the medication's effect on gastric emptying. Your doctor should monitor your thyroid function (TSH levels) when starting semaglutide or changing the dose, and may need to adjust your levothyroxine dose accordingly.
Warfarin and other oral anticoagulants (blood thinners) may also be affected. Because semaglutide slows gastric emptying, the absorption pattern of warfarin may change, potentially affecting how quickly your blood clots. Your doctor may need to check your INR (International Normalized Ratio) more frequently when you start or stop semaglutide.
Minor Interactions
While semaglutide delays gastric emptying, clinical pharmacology studies have shown that it does not have a clinically meaningful effect on the absorption of most oral medications, including oral contraceptives, atorvastatin, digoxin, and metformin. However, because individual responses can vary, it is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs, vitamins, and herbal supplements.
What Is the Correct Dosage of Semaglutide?
Oral semaglutide (Rybelsus) starts at 1.5 mg once daily for one month, then increases to 4 mg, with possible further titration to 9 mg, 25 mg, or 50 mg. Injectable semaglutide (Ozempic) starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg, with possible increase to 1 mg or 2 mg. Always follow your doctor's specific dosing instructions.
Semaglutide dosing follows a gradual titration schedule to minimize gastrointestinal side effects such as nausea and vomiting. Your doctor will determine the appropriate starting dose and target dose based on your specific condition, response to treatment, and tolerability. Never change your dose without consulting your healthcare provider.
Oral Semaglutide (Rybelsus) Dosing
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Starting dose | 1.5 mg once daily | 1 month | Dose initiation, tolerance building |
| First increase | 4 mg once daily | At least 1 month | Initial therapeutic dose |
| Titration (if needed) | 9 mg once daily | At least 1 month | Standard therapeutic dose |
| Higher dose (if needed) | 25 mg once daily | At least 1 month | Enhanced glycemic/weight control |
| Maximum dose | 50 mg once daily | Ongoing | Maximum therapeutic effect |
The oral tablet must be taken on an empty stomach after fasting for at least 8 hours (typically first thing in the morning). Swallow the tablet whole with a small amount of water (up to 120 ml / half a glass). Do not split, crush, or chew the tablet. Wait at least 30 minutes after taking the tablet before eating, drinking anything other than water, or taking other oral medications. Failure to follow these instructions significantly reduces the absorption of semaglutide.
Injectable Semaglutide (Ozempic) Dosing for Type 2 Diabetes
Ozempic Titration Schedule
- Weeks 1–4: 0.25 mg subcutaneously once weekly (initiation dose, not therapeutic)
- Weeks 5+: 0.5 mg subcutaneously once weekly
- If additional control needed: May increase to 1 mg once weekly after at least 4 weeks
- Maximum dose: 2 mg once weekly (after at least 4 weeks on 1 mg)
Injectable Semaglutide (Wegovy) Dosing for Weight Management
Wegovy Titration Schedule
- Weeks 1–4: 0.25 mg subcutaneously once weekly
- Weeks 5–8: 0.5 mg subcutaneously once weekly
- Weeks 9–12: 1 mg subcutaneously once weekly
- Weeks 13–16: 1.7 mg subcutaneously once weekly
- Week 17+: 2.4 mg subcutaneously once weekly (maintenance dose)
Elderly Patients
No dose adjustment is required based on age. However, elderly patients may be more susceptible to gastrointestinal side effects and dehydration. Clinical experience in patients older than 75 years is limited. Close monitoring and careful dose titration are recommended for older adults, particularly those with renal impairment or those taking other medications that may affect kidney function.
Renal and Hepatic Impairment
No dose adjustment is required for patients with mild, moderate, or severe renal impairment. However, patients with kidney problems should be monitored closely for signs of dehydration, as gastrointestinal side effects (nausea, vomiting, diarrhea) can worsen renal function. Semaglutide is not recommended in patients with end-stage renal disease. No dose adjustment is required for patients with hepatic (liver) impairment.
Missed Dose
Oral semaglutide (Rybelsus): If you miss a dose, skip the missed dose and take your normal dose the next day. Do not take a double dose to make up for a missed one.
Injectable semaglutide (Ozempic/Wegovy): If a dose is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If the next scheduled dose is less than 2 days away, skip the missed dose and resume the regular dosing schedule. Do not administer two doses within 2 days of each other.
Overdose
If you take more semaglutide than prescribed, contact your doctor or seek medical attention immediately. Symptoms of overdose may include severe nausea, vomiting, and diarrhea, which can lead to dehydration. Treatment is supportive and symptom-based, as there is no specific antidote for semaglutide overdose. Clinical experience with overdose is limited.
Do not discontinue semaglutide without first talking to your doctor. If you stop taking the medication, your blood sugar levels may rise, and any weight loss achieved may be reversed. Your doctor can help you safely manage any changes to your treatment regimen.
What Are the Side Effects of Semaglutide?
The most common side effects of semaglutide are gastrointestinal: nausea, diarrhea, and vomiting, which affect more than 1 in 10 users. These usually improve over time. Serious but rare side effects include pancreatitis, diabetic retinopathy complications, severe allergic reactions, and non-arteritic anterior ischemic optic neuropathy (NAION). Contact your doctor immediately if you experience severe abdominal pain, vision changes, or signs of a serious allergic reaction.
Like all medicines, semaglutide can cause side effects, although not everyone experiences them. Most side effects are gastrointestinal in nature and tend to occur during the dose-escalation phase, becoming less frequent as the body adjusts to the medication. Below is a comprehensive overview of side effects organized by frequency.
Serious Side Effects
- Severe, persistent abdominal pain (possibly radiating to the back) – may indicate acute pancreatitis
- Severe allergic reactions (anaphylaxis) – difficulty breathing, swelling of face/throat, wheezing, rapid heartbeat, pale cold skin
- Sudden vision loss or rapid vision deterioration – may indicate NAION ("stroke of the eye")
- Severe abdominal bloating with vomiting – may indicate intestinal obstruction
Side Effects by Frequency
Very Common (more than 1 in 10 users)
- Nausea – the most frequently reported side effect; usually decreases with continued use
- Diarrhea – typically mild to moderate and resolves over time
- Low blood sugar (hypoglycemia) when used with sulfonylurea or insulin
Common (up to 1 in 10 users)
- Vomiting – usually improves over time; may occur more frequently at higher doses (25 mg and 50 mg)
- Decreased appetite
- Dizziness
- Abdominal pain
- Abdominal bloating
- Constipation
- Dyspepsia (indigestion)
- Gastritis (stomach inflammation) – may present as stomach pain, nausea, or vomiting
- Gastroesophageal reflux disease (acid reflux, heartburn)
- Flatulence (gas)
- Fatigue
- Increased pancreatic enzymes (lipase and amylase) in blood tests
- Altered skin sensation (paresthesia) – usually resolves; may be more frequent with higher doses
- Headache
- Complications of diabetic retinopathy (eye disease)
- Low blood sugar when used with other oral diabetes medications
Uncommon (up to 1 in 100 users)
- Allergic reactions (rash, itching, or hives)
- Changes in taste perception (dysgeusia)
- Rapid heart rate (tachycardia)
- Belching (eructation)
- Delayed gastric emptying
- Gallstones (cholelithiasis)
- Weight loss (when used for diabetes)
Rare (up to 1 in 1,000 users)
- Severe allergic reactions (anaphylaxis) – seek immediate medical attention
- Acute pancreatitis (inflammation of the pancreas) – seek immediate medical attention
Very Rare (up to 1 in 10,000 users)
- Non-arteritic anterior ischemic optic neuropathy (NAION) – "stroke of the eye" causing vision loss without pain; seek immediate medical attention
Hypoglycemia Warning Signs
When semaglutide is used with sulfonylureas or insulin, low blood sugar (hypoglycemia) can occur. Warning signs may appear suddenly and include:
- Cold sweats, cold and pale skin
- Headache and rapid heartbeat
- Nausea or intense hunger
- Visual changes, drowsiness, or weakness
- Nervousness, anxiety, or confusion
- Difficulty concentrating or trembling
Your doctor will instruct you on how to treat low blood sugar and what to do when you notice these warning signs. Always carry a source of fast-acting sugar (glucose tablets, fruit juice, or regular soda) in case of a hypoglycemic episode.
How Should You Store Semaglutide?
Oral semaglutide tablets (Rybelsus) should be stored in their original packaging to protect from light and moisture, at room temperature. Injectable semaglutide (Ozempic, Wegovy) pens that are not in use should be stored in the refrigerator (2–8°C). Once in use, injection pens can be stored at room temperature (below 30°C) for up to 6 weeks.
Oral Tablets (Rybelsus)
Store Rybelsus tablets in their original blister packaging to protect them from light and moisture. No special temperature storage requirements apply – store at room temperature. Keep the medicine out of sight and reach of children. Do not use after the expiration date printed on the blister pack and carton (after "EXP"). The expiration date refers to the last day of the stated month.
Injectable Pens (Ozempic, Wegovy)
Before first use, store pre-filled injection pens in a refrigerator at 2–8°C (36–46°F). Do not freeze, and do not use if the product has been frozen. Keep away from the cooling element of the refrigerator. Protect from light by keeping the pen in the original carton.
After first use, store the pen at room temperature (below 30°C / 86°F) or in a refrigerator (2–8°C / 36–46°F) for up to 6 weeks. Always keep the pen cap on when not in use to protect from light. Do not use this medicine if the solution appears cloudy, discolored, or contains particles.
General Disposal
Do not dispose of medications in wastewater or household waste. Return any unused or expired medication to your pharmacy for proper disposal. Used injection needles should be placed in a sharps disposal container and returned to your pharmacy or healthcare facility. These measures help protect the environment.
What Does Semaglutide Contain?
Each tablet of Rybelsus contains semaglutide as the active ingredient (available in 1.5 mg, 4 mg, 9 mg, 25 mg, and 50 mg strengths) along with salcaprozate sodium (an absorption enhancer) and magnesium stearate. The injectable forms (Ozempic, Wegovy) contain semaglutide in a phosphate buffer solution with propylene glycol and phenol as preservative.
Oral Tablets (Rybelsus)
Active substance: Semaglutide. Each tablet contains 1.5 mg, 4 mg, 9 mg, 25 mg, or 50 mg of semaglutide.
Other ingredients: Salcaprozate sodium (SNAC) – a unique absorption enhancer that enables oral delivery of semaglutide by protecting the peptide from enzymatic degradation in the stomach and facilitating absorption across the gastric mucosa. Magnesium stearate serves as a lubricant.
Tablet appearance: The 1.5 mg, 4 mg, and 9 mg tablets are white to light yellow and round (6.5 mm in diameter), debossed with the dose on one side and "novo" on the other. The 25 mg and 50 mg tablets are white to light yellow and oval (6.8 mm × 12 mm), debossed similarly. Tablets are available in aluminum/aluminum blister packs in pack sizes of 10, 30, 60, 90, and 100 tablets.
Injectable Solution (Ozempic, Wegovy)
Active substance: Semaglutide in solution for injection in a pre-filled pen.
Other ingredients: Disodium phosphate dihydrate, propylene glycol, phenol, sodium hydroxide or hydrochloric acid (for pH adjustment), and water for injection.
Pen appearance: Clear, colorless or almost colorless solution in a pre-filled, disposable pen. Each pen delivers multiple doses; the number of doses varies by product and strength.
Frequently Asked Questions About Semaglutide
Semaglutide is a GLP-1 receptor agonist used primarily for two conditions: type 2 diabetes mellitus and chronic weight management. For diabetes, it helps lower blood sugar levels by stimulating insulin production and suppressing glucagon in a glucose-dependent manner. For weight management, it reduces appetite and food intake. It is available under three brand names: Rybelsus (oral tablets for diabetes), Ozempic (weekly injection for diabetes), and Wegovy (weekly injection for weight management). It has also been shown to reduce cardiovascular risk in patients with type 2 diabetes and established cardiovascular disease.
The most common side effects are gastrointestinal: nausea (affecting more than 1 in 10 users), diarrhea, and vomiting. These typically occur during the dose-escalation phase and improve as the body adjusts to the medication over several weeks. Other common side effects include decreased appetite, abdominal pain, constipation, dyspepsia (indigestion), fatigue, and headache. Most side effects are mild to moderate in severity. If gastrointestinal symptoms are persistent or severe, contact your healthcare provider.
Take Rybelsus on an empty stomach, ideally first thing in the morning after fasting for at least 8 hours. Swallow the tablet whole with a small amount of plain water (up to 120 ml or about half a glass). Do not crush, split, or chew the tablet, as this may affect absorption. After taking the tablet, wait at least 30 minutes before eating, drinking anything other than plain water, or taking any other oral medications. Following these instructions is essential because only a small fraction of semaglutide is absorbed, and deviating from these guidelines will further reduce absorption and effectiveness.
No, semaglutide should not be used during pregnancy or breastfeeding. Its effects on the developing fetus are not known, and you must use effective contraception while taking this medication. If you plan to become pregnant, discuss with your doctor about stopping semaglutide at least 2 months before trying to conceive. Semaglutide passes into breast milk, and its effects on the nursing infant are unknown, so breastfeeding is not recommended during treatment.
All three medications contain semaglutide as the active ingredient but differ in formulation, dosing, and approved indications. Ozempic is a once-weekly subcutaneous injection approved for the treatment of type 2 diabetes (doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg). Wegovy is also a once-weekly subcutaneous injection but is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities (maintenance dose: 2.4 mg). Rybelsus is a daily oral tablet approved for type 2 diabetes (doses: 1.5 mg, 4 mg, 9 mg, 25 mg, 50 mg). The choice between them depends on your specific medical condition, preferences, and your doctor's recommendation.
Yes, weight loss is a well-documented effect of semaglutide. In the STEP clinical trial program for Wegovy, participants achieved an average body weight reduction of approximately 15–17% compared to baseline. Even at lower doses used for diabetes (Ozempic), clinically significant weight loss of 4–6 kg on average has been observed. The weight loss is primarily driven by reduced appetite and food intake through semaglutide's effects on appetite centers in the brain, combined with delayed gastric emptying. However, weight loss varies among individuals, and semaglutide should be used as part of a comprehensive weight management program including diet and exercise.
For oral semaglutide (Rybelsus): skip the missed dose and take your normal dose the next day. Do not take two tablets to make up for a missed one. For injectable semaglutide (Ozempic or Wegovy): if the next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as possible. If the next dose is less than 2 days away, skip the missed dose and continue with your regular schedule. Never inject two doses within 2 days of each other.
References
This article is based on the following evidence-based sources and international medical guidelines:
- European Medicines Agency (EMA). Ozempic (semaglutide) – Summary of Product Characteristics. Last updated 2025. Available at: EMA – Ozempic
- European Medicines Agency (EMA). Rybelsus (semaglutide) – Summary of Product Characteristics. Last updated 2025. Available at: EMA – Rybelsus
- European Medicines Agency (EMA). Wegovy (semaglutide) – Summary of Product Characteristics. Last updated 2025. Available at: EMA – Wegovy
- U.S. Food and Drug Administration (FDA). Ozempic Prescribing Information. Novo Nordisk, 2024.
- U.S. Food and Drug Administration (FDA). Wegovy Prescribing Information. Novo Nordisk, 2024.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- American Diabetes Association. Standards of Care in Diabetes – 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy. Diabetes Care. 2019;42(9):1724-1732.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786.
Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, which includes specialists in endocrinology, diabetology, and clinical pharmacology.
iMedic Medical Editorial Team – Licensed physicians with specialist training in endocrinology and clinical pharmacology. Evidence-based content following EMA, FDA, and ADA guidelines.
iMedic Medical Review Board – Independent medical experts who verify clinical accuracy, evidence quality, and guideline adherence. All content is reviewed according to international medical standards.
All medical information on iMedic is evidence-based, peer-reviewed, and independently produced without commercial funding or pharmaceutical industry sponsorship. Our editorial process follows the GRADE evidence framework to ensure the highest quality of medical information.